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review rounds. With the in-depth review, articles did not 
meet inclusion because of invalid intervention (13 cost 
computation studies referring to costs described in a previous 
publication, 7 literature reviews, 10 articles not formally 
describing cost calculation) or design (n=11)  .  
 
Among the selected studies (table 1), the scope of the 
calculation varies from a comprehensive departmental 
perspective to disease-, treatment- and activity-specific 
calculations (e.g. respiratory-gated RT). Their costing 
methodologies range from detailed micro costing approaches 
(n=5) to the pragmatic activity-based costing (ABC, n=4) and 
time-driven activity-based costing (TD ABC, n=1) methods. 
Besides these established accounting methods, five studies 
developed “home-made” approaches. Not surprisingly, costs 
found in these studies vary greatly. 
 
 
 
Conclusions: While the advantages of ABC and TD-ABC for 
cost analysis have been established in the cost accounting 
literature, only one third of the studies identified have 
adopted one of these methodologies. Just as clinical studies, 
sound cost calculations require high quality input data and an 
appropriate costing methodology in order to facilitate 
comparison across studies. Robust costing exercises are a 
necessary basis to perform full economic evaluations and to 
allow accurate reimbursement setting, both key in the 
optimal allocation of health care resources.  
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Purpose/Objective: External beam radiotherapy is frequently 
used to palliate pelvic symptoms of castration resistant 
prostate cancer (CRPC). Documentation of palliative effect, 
toxicity and a recommended treatment schedule are lacking. 
The aims of the study were to evaluate changes in symptom 
severity, quality of life (QOL) and degree of toxicity among 
patients with CRPC following palliative pelvic radiotherapy 
(PPRT). 
Materials and Methods: Patients with CRPC and a 
symptomatic pelvic mass who were prescribed PPRT with 30-
39 Gy in 3 Gy fractions were eligible for inclusion. Treatment 
volume included the primary tumor and/or pelvic lymph node 
metastases as clinically indicated. Subjects were asked to 
identify a target symptom (TS), defined as their principal 
pelvic complaint requiring palliation. The primary outcome 
was patients' self-reported TS severity relative to baseline, 
12 weeks after PPRT. Patient-reported symptoms and QOL 
(measured using EORTC QLQ C30 and PR25) were assessed 
before, at the end of, and 6 and 12 weeks after PPRT. 
Results: Forty-seven patients were included and 40 were 
evaluable at the 12 week follow-up. Median age was 79 years 
(60–93). Median radiotherapy dose delivered was 36 Gy (27–
39). Lower urinary tract symptoms (LUTS) (n=21), 
macroscopic hematuria (n=12), and pelvic pain (n=9) were 
the most common TS. 28/40 (70%) evaluable patients 
reported that their TS had either resolved or improved 12 
weeks after PPRT and in an additional 10/40 (25%), the TS 
severity was unchanged. Forty-one of the 47 included 
patients (87%) reported complete resolution or improvement 
of the TS at at least one of the three follow-up visits. 
Hematuria responded most rapidly and consistently with all 
evaluable patients reporting improvement or resolution at 12 
weeks. The course of LUTS response was more variable, with 
8/18 (44%) patients reporting improved or resolved LUTS at 
the 12 week follow-up. Pelvic pain relief 12 weeks after PPRT 
was experienced by 7/9 (78%) patients who identified it as 
their TS while their use of opioids decreased. Non-target 
pelvic symptom severity decreased over the course of the 
study. Clinically relevant improvement in global QOL score 
(50-66.7 points; p=0.032) was seen 6 weeks after 
radiotherapy and otherwise remained stable at follow-up 
visits. There was no grade 4 toxicity. 
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Conclusions: In the majority of patients with progressive 
CRPC and a symptomatic pelvic tumor, PPRT with 30-39 Gy 
contributes to relief of macroscopic hematuria, pain and 
other pelvic symptoms as well as improved QOL, with little 
toxicity. Future studies should investigate whether PPRT 
regimens can be further simplified.  
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Purpose/Objective: The therapeutic ratio of antalgic 
radiotherapy for bone metastases might be improved by 
decreasing the radiotherapy dose to the normal tissue and/or 
by increasing the dose to the bone metastases. A three arm 
randomized phase II trial comparing single fraction 
conventional radiotherapy with 2 different dose levels of 
single fraction Biological Image Guided Stereotactic 
RadioSurgery (BIG-SRS) will allow us to select the treatment 
arm with sufficient promise of efficacy to justify its 
evaluation in a definitive phase III trial. 
Materials and Methods: Patients with painful bone 
metastases without major neurological symptoms were 
enrolled. All patients underwent a 18[F]-FDG-PET-CT prior to 
irradiation. Patients were randomized (1:1:1) to receive 
either 8 Gy in a single fraction with conventional 
radiotherapy (arm A) or 8 Gy in a single fraction with dose-
painting-by-numbers (DPBN) (dose range between 6 and 10 
Gy) (arm B) or 16 Gy in a single fraction with DPBN (dose 
range between 14 and 18 Gy) (arm C). The primary endpoint 
was overall pain response at 1 month, defined as the sum of 
complete and partial pain responses to treatment assessed 
using a visual analogue scale (range 0-10). Analysis was done 
by intention to treat and pairwise tests are based on a score 
statistic and Fisher's information pairs. The arm with the 
highest score statistic is selected as the most promising to 
continue in phase III. 
Results: 
 
Forty-five patients were randomized to a treatment group. 
Eight patients (53%), 12 patients (80%) and 9 patients (60%) 
had an overall response to treatment in arm A, B and C, 
respectively. The estimated odds ratio of arm A vs B is 3.5 
(95% CI: 0.44-17.71) with a score statistic of 2.4 (p = 0.12). 
Patients in Arm B showed a significant improvement in QOL 
score at 1 month compared with Arm A (pain characteristic, 
insomnia and appetite loss, p<0.05). The estimated odds 
ratio of arm A vs C is 1.31 (95% CI: 0.31-5.58) with a score 
statistic of 0.14 (p = 0.71). No differences in QOL between 
Arm A and C were observed. 
Conclusions: A single fraction of 8 Gy by means of BIG-SRS 
shows a promising overall pain response of 80%, meriting 
further evaluation in phase III.  
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